Synthesis, biological activity and docking study of imidazol-5-one as novel non-nucleoside HIV-1 reverse transcriptase inhibitors

Santosh N Mokale; Deepak Lokwani; Devanand B Shinde

doi:10.1016/j.bmc.2012.02.037

Synthesis, biological activity and docking study of imidazol-5-one as novel non-nucleoside HIV-1 reverse transcriptase inhibitors

Bioorg Med Chem. 2012 May 1;20(9):3119-27. doi: 10.1016/j.bmc.2012.02.037. Epub 2012 Mar 17.

Authors

Santosh N Mokale¹, Deepak Lokwani, Devanand B Shinde

Affiliation

¹ Dr. Rafiq Zakaria Campus, YB Chavan College of Pharmacy, Aurangabad, Maharashtra, India.

PMID: 22480850
DOI: 10.1016/j.bmc.2012.02.037

Abstract

A novel series of substituted imidazol-5-ones were designed, synthesized and evaluated for in vitro reverse transcriptase (RT) inhibition activity using reverse transcriptase assay kit (Roche, Colorimetric). It has been observed from in vitro screening that newly synthesized compounds possess RT inhibitory activity. Docking study was performed to study the binding orientation and affinity of synthesized compounds for RT enzyme.

MeSH terms

Binding Sites
Computer Simulation
HIV Reverse Transcriptase / antagonists & inhibitors*
HIV Reverse Transcriptase / metabolism
HIV-1 / drug effects
Humans
Imidazoles* / chemical synthesis
Imidazoles* / chemistry
Imidazoles* / pharmacology
Protein Structure, Tertiary
Reverse Transcriptase Inhibitors* / chemical synthesis
Reverse Transcriptase Inhibitors* / chemistry
Reverse Transcriptase Inhibitors* / pharmacology
Structure-Activity Relationship

Substances

Imidazoles
Reverse Transcriptase Inhibitors
imidazole
reverse transcriptase, Human immunodeficiency virus 1
HIV Reverse Transcriptase